Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on July 17, 2013. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Dr. John F. Milligan as a Class I director, effective July 17, 2013. Dr. Milligan was also appointed to the Audit Committee and the Compensation Committee. He currently serves as President and Chief Operating Officer of Gilead Sciences, Inc.
Guidance, Outlook, and Compensation
There is no financial guidance or outlook provided in this filing. The document details the following compensatory arrangements for Dr. Milligan:
- Annual Retainer: $35,000 for board service.
- Committee Retainers: $10,000 for the Audit Committee and $7,000 for the Compensation Committee.
- Equity Grant: An automatic stock option to purchase 35,000 shares of common stock was granted on the date of appointment.
Investor Verification Checklist
- Verify Dr. Milligan's current role and tenure at Gilead Sciences, Inc.
- Confirm the vesting schedule and exercise price of the 35,000 stock options granted.
- Review the press release dated July 18, 2013 (Exhibit 99.1) for additional context on the appointment.
- Check for any potential conflicts of interest given Dr. Milligan's position at a competitor or partner firm.